🏆 Deal of the Week · CW 47/2023
Universal DX raised $70 million in a Series B round; the company's valuation was not disclosed. The financing was announced in November 2023 and was recognised as Venionaire DealMatrix's Deal of the Week for KW 47/2023. Investor details for the round were not publicly itemised at the time of reporting.
Universal DX — key deal facts
| Company | Universal DX |
| Founded | 2012 |
| Headquarters | Seville, Spain |
| Amount raised | 70M USD |
| Valuation | Valuation Remains Undisclosed |
| Round | Series B |
| Investors | undefined |
| Sectors | BioPharma |
Who invested in Universal DX?
Specific investor names for the Series B have not been disclosed in verified sources. The round's undisclosed investor composition is notable given the scale of the raise — $70 million — for a pre-revenue-stage liquid biopsy platform operating out of Spain. Further investor detail may be confirmed via the source article published by GenomeWeb.
What does Universal DX do?
Universal DX, formally Universal Diagnostics S.A., is a Spanish biotech company founded in 2012 by Juan Martinez-Barea and headquartered in Seville, Spain. The company develops minimally-invasive, blood-based liquid biopsy tests for the early detection of cancer. Its lead product, Signal-C®, targets colorectal cancer screening and is built on a proprietary methylation marker panel combined with next-generation sequencing and AI-driven bioinformatics. The platform is designed to extend beyond colorectal cancer to detect liver, lung, pancreatic, and gastric cancers from a single blood draw. Alongside the Series B close, Universal DX inked a deal with Quest Diagnostics to provide its colorectal cancer test.
Universal DX valuation & multiples
No existing multiples figures were provided for this deal. Given that Universal DX operates in the BioPharma and liquid biopsy diagnostics segment, relevant benchmarks would typically include EV/Sales and EV/EBITDA multiples for comparable molecular diagnostics and early-cancer-detection companies. Explore Venionaire DealMatrix's BioPharma sector multiples pages for current trading and transaction comparable ranges.
Explore the benchmarks: Series B.
Frequently asked questions
How much did Universal DX raise in its Series B?
Universal DX raised $70 million in its Series B round, announced in November 2023.
What is Universal DX's valuation?
Universal DX's valuation was not disclosed in connection with the Series B round.
Who invested in Universal DX?
The specific investors in Universal DX's Series B have not been publicly disclosed in verified sources.
When was Universal DX founded and where is it based?
Universal DX was founded in 2012 and is headquartered in Seville, Spain.
Source: original announcement — read the full report.